From fixed activities to personalized treatments in radionuclide therapy: lost in translation? by Flux, G.D. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/191643
 
 
 
Please be advised that this information was generated on 2018-06-17 and may be subject to
change.
LETTER TO THE EDITOR
From fixed activities to personalized treatments in radionuclide
therapy: lost in translation?
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We read with interest the letter by Giammarile et al. [1] ad-
dressing our editorial in which we proposed that the European
Medicines Agency should allow the option of a dosimetry-
based approach to the treatment of cancer with radionuclide
therapy [2]. Our editorial was intended to draw attention to the
potential legal issues of recommending an approach to treat-
ment that could contravene the European Council Directive
2013/59 [3] and national legislation, as the directive (article
56) states that “For all medical exposure of patients for
radiotherapeutic1 purposes, exposures of target volumes shall
be individually planned and their delivery appropriately veri-
fied...”. This directive is intended to “lay down basic safety
standards for the protection of dangers arising from exposure
to ionizing radiation” and emphasizes the need for ‘justifica-
tion’ and ‘optimization’ of intentional radiation exposures of
patients.
We do not agree with the conclusion of this letter that
cancer therapy with radiopharmaceuticals should be devel-
oped “in a similar manner to chemotherapeutics^, “indepen-
dent of tumor load and metastases^ and is “better character-
ized as a tumor-selective treatment modality with more simi-
larities to systemic chemotherapy”.
In any scientific field concerned with biological effects of
radiation, whether for therapy or radiation protection pur-
poses, the effects of radiation on tissue are primarily depen-
dent on the well-established measure absorbed dose.
Consequently, great efforts are made to calculate absorbed
doses in cells, tissues, and organs. The hypothesis that the
level of activity administered has a greater impact on treat-
ment outcome than the subsequent biodistribution, the radia-
tion delivery and the absorbed dose is ignoring the results of
decades of radiation research on biological systems.
1 According to the Directive (article 4, definition (81)) Bradiotherapeutic^
means pertaining to radiotherapy, including nuclear medicine for therapeutic
purposes^
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Still, today, prescriptions in radionuclide therapy are most
commonly based on a fixed amount of activity for all patients,
sometimes tailored to patientweight or body surface area.While
this enables therapy to be performedwithminimal resourcing or
planning, we contend that the development of personalized pre-
scription alternatives based on dosimetry are likely to improve
the outcome and cost-benefit of radionuclide therapies. There is
increasing evidence that treatment outcome correlates with the
absorbeddosesdelivered to tumorsand tohealthyorgans [4].For
example, in a recent multivariate analysis on radioembolization
in hepatocellular carcinoma, lesion absorbed dose was the only
factor associated with prolonged overall survival [5]. We agree
with Giammarile et al. that it is unfortunate that there have been
no randomized controlled trials to evaluate the respective merits
of dosimetry-based versus fixed-activity approaches. This need
has longbeen acknowledged [6] andwe certainly encourage and
will support any initiatives in this area. However, the absence of
trials cannot be regarded as a valid reason to hinder the develop-
ment of dosimetry-based prescriptions and does not justify the
avoidance of post-treatment verification of the absorbed doses
delivered, which provides patient-specific information without
changing patientmanagement. Progress inmedicine necessarily
entails the introduction of new concepts for which there is a
hypothesis of clinical benefit, so that evidence can then be ob-
tained to support or refute such hypotheses. The emergence of
PETand PET/CTwere strongly supported and endorsed by nu-
clear medicine before clinical evidence became available.
Undoubtedly, the implementation of dosimetry-based treat-
ment planning and the verification of the absorbed doses de-
livered following administrations will entail a major reapprais-
al of the way in which these treatments are conventionally
handled. As Giammarile et al. highlighted, there are a number
of challenges to be addressed. These include resourcing and
training, and possibly new ideas on how to organize the treat-
ment. Such challenges are by no means unique for radionu-
clide therapy, and should be considered within the perspective
of the introduction and evaluation of new techniques in other
radiotherapy fields, building on fruitful collaborations be-
tween different medical specialties in nuclear medicine, on-
cology, and medical physics. Training and professional devel-
opment is necessary and available, not least via the EANM
ESMIT teaching initiatives as well as the DoMore track of the
EANM annual congress.
A number of justifications are frequently presented to avoid
dosimetry. While an absorbed dose calculation is subject to
uncertainties that stem from the methodology chain that
covers activity determination to the absorbed dose calculation,
there is abundant evidence that simplistic prescription
methods, based on fixed activities, deliver a range of absorbed
doses to normal organs and tumors that are far greater than
methodological uncertainties (see e.g., [7–16]).
The role of radiobiology to examine the impact of
radioresistance, low and continuous absorbed dose rates, and
heterogeneity of uptake at either a cellular, microscopic or
macroscopic scale is under investigation, and will expand if
dosimetry data are made available to compare with outcomes.
We believe that this research field should be encouraged to
fully develop the theragnostic advantage that radionuclide
therapy can offer.
It is sometimes claimed that the cost of dosimetry is prohib-
itive. While this may be an issue for established inexpensive
treatments, the same cannot be said of the large number of
emerging radiopharmaceuticals, for which the cost of extra
scans and physics time is minimal in comparison with the cost
of the drug itself. It is incongruous to invest heavily in the de-
velopment of a new drug, but then to forego clinical optimiza-
tionof thatdrug.Healtheconomicstudiesarewarranted,where-
by the cost of dosimetrymay bemeasured against the potential
cost savings of more individualized and optimized treatments.
We endorse the Basic Safety Standards directive of the
European Union [3], which states that radiotherapeutic proce-
dures should be both planned and verified. Physicians, medical
physicists, and all disciplines within nuclear medicine should
jointly promote any efforts that lead to best patient care and that
mayminimize avoidable short- and long-term toxicity.We fore-
see a bright future for radionuclide therapy in which dosimetry-
based personalized treatments are developed by multidisciplin-
ary engagement, and look forward to continuing discussions on
how this should be translated into clinical practice.
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